OBI breast cancer therapy misses Phase II/III endpoint

OBI Pharma Inc. (TPEx:4174) said OBI-822/821 missed the primary endpoint of progression free survival (PFS) in a top-line analysis of its Phase II/III study to treat metastatic breast cancer. The company said the data showed a significant PFS improvement among patients who had an immune response to the therapy.

OBI said it plans to discuss with regulators the design of a planned global Phase III study of the candidate. ...